Form 4: Celldex Therapeutics Director Acquires Stock Options

Harry Penner Jr., a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, under the company's 2021 Omnibus Equity Incentive Plan.

Summary

• On June 13, 2024, Harry Penner Jr., a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options.
• The options were granted under the company's 2021 Omnibus Equity Incentive Plan.
• The exercise price of the options is $36.43.
• The options become exercisable on June 13, 2025, and expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock option grants, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates